341 related articles for article (PubMed ID: 30832407)
1. Dietary Polyphenols Protect Against Oleic Acid-Induced Steatosis in an in Vitro Model of NAFLD by Modulating Lipid Metabolism and Improving Mitochondrial Function.
Rafiei H; Omidian K; Bandy B
Nutrients; 2019 Mar; 11(3):. PubMed ID: 30832407
[TBL] [Abstract][Full Text] [Related]
2. Comparison of dietary polyphenols for protection against molecular mechanisms underlying nonalcoholic fatty liver disease in a cell model of steatosis.
Rafiei H; Omidian K; Bandy B
Mol Nutr Food Res; 2017 Sep; 61(9):. PubMed ID: 28317281
[TBL] [Abstract][Full Text] [Related]
3. Procyanidin B2 ameliorates free fatty acids-induced hepatic steatosis through regulating TFEB-mediated lysosomal pathway and redox state.
Su H; Li Y; Hu D; Xie L; Ke H; Zheng X; Chen W
Free Radic Biol Med; 2018 Oct; 126():269-286. PubMed ID: 30142454
[TBL] [Abstract][Full Text] [Related]
4. The beneficial effects of resveratrol on steatosis and mitochondrial oxidative stress in HepG2 cells.
Izdebska M; Piątkowska-Chmiel I; Korolczuk A; Herbet M; Gawrońska-Grzywacz M; Gieroba R; Sysa M; Czajkowska-Bania K; Cygal M; Korga A; Dudka J
Can J Physiol Pharmacol; 2017 Dec; 95(12):1442-1453. PubMed ID: 28759727
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory effect of blueberry polyphenolic compounds on oleic acid-induced hepatic steatosis in vitro.
Liu Y; Wang D; Zhang D; Lv Y; Wei Y; Wu W; Zhou F; Tang M; Mao T; Li M; Ji B
J Agric Food Chem; 2011 Nov; 59(22):12254-63. PubMed ID: 21999238
[TBL] [Abstract][Full Text] [Related]
6. PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells.
Rogue A; Anthérieu S; Vluggens A; Umbdenstock T; Claude N; de la Moureyre-Spire C; Weaver RJ; Guillouzo A
Toxicol Appl Pharmacol; 2014 Apr; 276(1):73-81. PubMed ID: 24534255
[TBL] [Abstract][Full Text] [Related]
7. Phytotherapy using blueberry leaf polyphenols to alleviate non-alcoholic fatty liver disease through improving mitochondrial function and oxidative defense.
Li Z; Zhang H; Li Y; Chen H; Wang C; Wong VKW; Jiang Z; Zhang W
Phytomedicine; 2020 Apr; 69():153209. PubMed ID: 32240928
[TBL] [Abstract][Full Text] [Related]
8. Pretreatment of hydroethanolic extract of Dillenia indica L. attenuates oleic acid induced NAFLD in HepG2 cells via modulating SIRT-1/p-LKB-1/AMPK, HMGCR & PPAR-α signaling pathways.
Poornima MS; Sindhu G; Billu A; Sruthi CR; Nisha P; Gogoi P; Baishya G; G Raghu K
J Ethnopharmacol; 2022 Jun; 292():115237. PubMed ID: 35351574
[TBL] [Abstract][Full Text] [Related]
9. The role of hepassocin in the development of non-alcoholic fatty liver disease.
Wu HT; Lu FH; Ou HY; Su YC; Hung HC; Wu JS; Yang YC; Wu CL; Chang CJ
J Hepatol; 2013 Nov; 59(5):1065-72. PubMed ID: 23792031
[TBL] [Abstract][Full Text] [Related]
10. Antioxidant dietary approach in treatment of fatty liver: New insights and updates.
Ferramosca A; Di Giacomo M; Zara V
World J Gastroenterol; 2017 Jun; 23(23):4146-4157. PubMed ID: 28694655
[TBL] [Abstract][Full Text] [Related]
11. Swertiamarin ameliorates oleic acid induced lipid accumulation and oxidative stress by attenuating gluconeogenesis and lipogenesis in hepatic steatosis.
Patel TP; Rawal K; Soni S; Gupta S
Biomed Pharmacother; 2016 Oct; 83():785-791. PubMed ID: 27490779
[TBL] [Abstract][Full Text] [Related]
12. Exendin-4 alleviates steatosis in an in vitro cell model by lowering FABP1 and FOXA1 expression via the Wnt/-catenin signaling pathway.
Khalifa O; Al-Akl NS; Errafii K; Arredouani A
Sci Rep; 2022 Feb; 12(1):2226. PubMed ID: 35140289
[TBL] [Abstract][Full Text] [Related]
13. Effects of
Mun J; Park J; Yoon HG; You Y; Choi KC; Lee YH; Kim K; Lee J; Kim OK; Jun W
J Med Food; 2019 Dec; 22(12):1262-1270. PubMed ID: 31834842
[TBL] [Abstract][Full Text] [Related]
14. Fisetin Protects Against Hepatic Steatosis Through Regulation of the Sirt1/AMPK and Fatty Acid β-Oxidation Signaling Pathway in High-Fat Diet-Induced Obese Mice.
Liou CJ; Wei CH; Chen YL; Cheng CY; Wang CL; Huang WC
Cell Physiol Biochem; 2018; 49(5):1870-1884. PubMed ID: 30235452
[TBL] [Abstract][Full Text] [Related]
15. Dihydromyricetin ameliorates oleic acid-induced lipid accumulation in L02 and HepG2 cells by inhibiting lipogenesis and oxidative stress.
Xie C; Chen Z; Zhang C; Xu X; Jin J; Zhan W; Han T; Wang J
Life Sci; 2016 Jul; 157():131-139. PubMed ID: 27265384
[TBL] [Abstract][Full Text] [Related]
16. Arctigenin protects against steatosis in WRL68 hepatocytes through activation of phosphoinositide 3-kinase/protein kinase B and AMP-activated protein kinase pathways.
Chen KY; Lin JA; Yao HY; Hsu AC; Tai YT; Chen JT; Hsieh MC; Shen TL; Hsu RY; Wu HT; Wang GH; Ho BY; Chen YP
Nutr Res; 2018 Apr; 52():87-97. PubMed ID: 29525610
[TBL] [Abstract][Full Text] [Related]
17. Electrophilic nitro-oleic acid reverses obesity-induced hepatic steatosis.
Khoo NKH; Fazzari M; Chartoumpekis DV; Li L; Guimaraes DA; Arteel GE; Shiva S; Freeman BA
Redox Biol; 2019 Apr; 22():101132. PubMed ID: 30769284
[TBL] [Abstract][Full Text] [Related]
18. Mesencephalic astrocyte-derived neurotrophic factor ameliorates steatosis in HepG2 cells by regulating hepatic lipid metabolism.
He M; Wang C; Long XH; Peng JJ; Liu DF; Yang GY; Jensen MD; Zhang LL
World J Gastroenterol; 2020 Mar; 26(10):1029-1041. PubMed ID: 32205994
[TBL] [Abstract][Full Text] [Related]
19. Growth hormone ameliorates high glucose-induced steatosis on in vitro cultured human HepG2 hepatocytes by inhibiting de novo lipogenesis via ChREBP and FAS suppression.
Villanueva-Ortega E; Méndez-García LA; Garibay-Nieto GN; Laresgoiti-Servitje E; Medina-Bravo P; Olivos-García A; Muñoz-Ortega MH; Ventura-Juárez J; Escobedo G
Growth Horm IGF Res; 2020; 53-54():101332. PubMed ID: 32698101
[TBL] [Abstract][Full Text] [Related]
20. Resveratrol Treatment Enhances the Cellular Response to Leptin by Increasing OBRb Content in Palmitate-Induced Steatotic HepG2 Cells.
Ardid-Ruiz A; Ibars M; Mena P; Del Rio D; Muguerza B; Arola L; Aragonès G; Suárez M
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31842467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
